Crohn's Disease

Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease
BioSpace
Tue, 07/30/24 - 11:34 am
Ventyx Biosciences
VTX958
Crohn's Disease
J&J Positions Tremfya as Stelara Successor with Strong Head-to-Head Data
BioSpace
Wed, 05/22/24 - 11:33 am
JNJ
Tremfya
Stelara
Crohn's Disease
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study
Reuters
Thu, 03/28/24 - 05:07 pm
Bristol Myers Squibb
Crohn's Disease
clinical trials
ozanimod
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Motley Fool
Sun, 10/29/23 - 08:44 pm
Roche
Eli Lilly
Pfizer
IBD
ulcerative colitis
Crohn's Disease
mirikizumab
FDA approves Celltrion’s subcutaneous Remicade biosimilar for IBD
Pharm
Mon, 10/23/23 - 05:20 pm
Celltrio
Zymfentra
ulcerative colitis
Crohn's Disease
biosimilars
Remicade
Takeda’s stem cell treatment Alofisel flunks phase 3 trial in Crohn's complication
Fierce Pharma
Thu, 10/19/23 - 10:07 am
Takeda
Crohn's Disease
Alofisel
clinical trials
stem cells
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Clinical Trials Arena
Tue, 10/17/23 - 11:45 am
JNJ
Janssen
clinical trials
Crohn's Disease
Tremfya
AbbVie trumpets Skyrizi's resounding win against J&J's Stelara in Crohn's disease
Fierce Pharma
Mon, 10/16/23 - 11:50 am
AbbVie
Akyrizi
JNJ
Stelara
Crohn's Disease
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
BioSpace
Thu, 10/12/23 - 05:22 pm
Eli Lilly
mirikizumab
Crohn's Disease
FDA
AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial
BioSpace
Wed, 09/13/23 - 11:36 am
AbbVie
Skyrizi
JNJ
Stelara
Crohn's Disease
clinical trials
AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report
BioSpace
Fri, 09/8/23 - 11:29 am
AbbVie
Humira
biosimilars
Crohn's Disease
Roche in Talks to Buy Stomach Drug from Roivant for $7B: Report
BioSpace
Fri, 07/14/23 - 11:56 am
Roche
Roivant
ulcerative colitis
Crohn's Disease
M&A
AbbVie's Rinvoq scores its 7th FDA nod, this one for Crohn's disease
Fierce Pharma
Thu, 05/18/23 - 08:36 pm
AbbVie
FDA
Rinvoq
Crohn's Disease
Humira
Amgen invests in TScan’s TargetScan platform for Crohn’s Disease breakthroughs
Medical Marketing and Media
Tue, 05/9/23 - 11:24 pm
Amgen
TScan
TargetScan
Crohn's Disease
Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor
Fierce Pharma
Fri, 02/10/23 - 11:09 am
Galapagos
FDA
filgotinib
Crohn's Disease
clinical trials
Jyseleca
BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports
PR Newswire
Sun, 12/4/22 - 01:24 pm
Bristol Myers Squibb
AbbVie
Zeposia
Skyrizi
ulcerative colitis
Crohn's Disease
gastroentrologists
Pfizer, Gilead and others seek clarifications on trial designs outlined in FDA's UC and Crohn's draft guidance
Endpoints
Thu, 07/21/22 - 10:38 am
Pfizer
Gilead Sciences
Big Pharma
ulcerative colitis
Crohn's Disease
drug development
FDA
FDA guidance machine churns out 8 new documents in less than a week
Endpoints
Mon, 05/2/22 - 06:17 pm
FDA
regulatory
ulcerative colitis
Crohn's Disease
cancer
clinical trials
J&J lands Tremfya one-two punch in IBD with first ulcerative colitis win and long-term Crohn's data
Fierce Pharma
Mon, 02/21/22 - 10:37 am
JNJ
Janssen
Tremfya
Crohn's Disease
Takeda bags Japanese approval for Crohn’s cell therapy Alofisel
Pharmaforum
Mon, 09/27/21 - 10:49 am
Takeda
Alofisel
cell therapy
Crohn's Disease
Japan

Pages